Nonalcoholic fatty liver disease (NAFLD) has become the most common cause of chronic liver disease in the Western world. NAFLD is a complex spectrum of liver diseases ranging from benign hepatic steatosis to its more aggressive necroinflammatory manifestation, nonalcoholic steatohepatitis (NASH). NASH pathogenesis is multifactorial and risk factors are almost identical to those of the metabolic syndrome. This has prompted substantial efforts to identify novel drug therapies for correcting underlying metabolic deficits, and to prevent or alleviate hepatic fibrosis in NASH. Available mouse models of NASH address different aspects of the disease, have varying clinical translatability, and, therefore, also show different utility in drug discovery.

非酒精性脂肪肝疾病（NAFLD）已成为西方世界慢性肝病的最常见原因。NAFLD是复杂的肝脏疾病，其范围从良性肝脂肪变性到更具侵略性的坏死性炎症表现，即非酒精性脂肪性肝炎（NASH）。NASH的发病机制是多因素的，危险因素与代谢综合征的危险因素几乎相同。这促使人们作出巨大的努力来确定新的药物疗法，以纠正潜在的代谢缺陷，并预防或减轻NASH中的肝纤维化。可用的NASH小鼠模型可解决疾病的不同方面，具有不同的临床可翻译性，因此在药物发现中也显示出不同的用途。